MYC and breast carcinoma: The lncRNA BCAR4 (breast cancer anti-estrogen resistance 4), originally identified in breast cancer, has been described to directly interact with and stabilize β-Catenin protein, which enhances the expression of Wnt target genes, such as MYC and CCND1, by preventing β-Catenin degradation [59].